Parallel enzymatic DNA synthesis using a semiconductor chip - Nature

This study presents a breakthrough in parallel enzymatic DNA synthesis using a semiconductor chip, offering a new pathway for high-throughput synthetic biology and diagnostics. While phosphoramidite s... Read original →

Integrating CMOS chips with enzymatic DNA synthesis is reshaping biomanufacturing’s foundational stack. Upstream, EUV and 3nm foundries like TSMC may be pulled into biochip supply chains, while downstream players such as Twist Bioscience face pressure to adapt to a new hardware paradigm. Regulatory-wise, the aqueous enzymatic process sidesteps toxic solvents, aligning with EU/US green chemistry mandates—but reliance on advanced nodes risks export controls, especially when involving Taiwan, China fabs. Competitively, Illumina could accelerate microfluidics acquisitions, while pure-play enzymatic firms like Ansa must prove scalability without semiconductor integration. Over the next 18 months, the real long-tail impact lies not in synthesis throughput but in DNA data storage standardization: control over the chip-enzyme-encoding protocol stack may dictate the interface architecture of molecular memory.